April 19, 2024
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-Conjugated Gamma Delta T-Cell Therapy, In Adult Subjects with Relapsed/Refractory CD20-Expressing B-Cell Malignancies
Select an appointment date and time from available spots listed below.